Drug-Resistant Epilepsy Market to Grow with a CAGR of 4.23% through 2028
Rising advancements in genetic testing and precision
medicine are expected to drive the Global Drug-Resistant Epilepsy Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Drug-Resistant
Epilepsy Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Drug-Resistant Epilepsy Market
stood at USD 1.05 billion in 2022 and is anticipated to grow with a CAGR of 4.23%
in the forecast period, 2024-2028. The increasing prevalence of epilepsy worldwide is a
major driver of the drug-resistant epilepsy market. According to the World
Health Organization (WHO), approximately 50 million people worldwide are
affected by epilepsy. Among them, a significant portion does not achieve
adequate seizure control with existing AEDs. As the global population continues
to grow and age, the prevalence of epilepsy is expected to rise, further
amplifying the demand for effective treatments for drug-resistant epilepsy. Diagnostic
advancements have played a crucial role in identifying and differentiating
drug-resistant epilepsy cases. Electroencephalography (EEG) and advanced
imaging techniques, such as magnetic resonance imaging (MRI) and positron
emission tomography (PET), have become more precise and accessible. These
technologies enable healthcare providers to better understand the underlying
causes of seizures and tailor treatment strategies, accordingly, driving the
demand for innovative therapies. Growing awareness about epilepsy and its
treatment options has led to earlier diagnosis and intervention. Public health
campaigns and educational initiatives have contributed to reduced stigma
associated with epilepsy, encouraging affected individuals to seek medical
attention sooner. Early diagnosis allows for more effective management of the
condition, including identifying drug-resistant cases early in the disease
course.
Pharmaceutical companies, academic institutions, and
healthcare providers are increasingly investing in research and development
efforts focused on drug-resistant epilepsy. This heightened commitment to
finding innovative solutions has led to the discovery of new therapeutic
targets, the development of novel AEDs with different mechanisms of action, and
the exploration of cutting-edge treatment modalities such as gene therapies and
targeted biologics. The concept of personalized medicine is gaining prominence
in the drug-resistant epilepsy market. By tailoring treatment plans to
individual patient profiles, healthcare providers can optimize the chances of
seizure control while minimizing side effects. This approach involves genetic
testing, neuroimaging, and patient-specific factors to determine the most
suitable treatment options. The move toward personalized medicine is expected
to improve patient outcomes and enhance the efficacy of drug-resistant epilepsy
therapies.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Drug-Resistant Epilepsy Market.”
Several emerging therapies are on the horizon,
offering hope for drug-resistant epilepsy patients. Responsive neurostimulation
systems, which detect and intervene in abnormal brain activity, have shown
promise in clinical trials. Additionally, novel AEDs with unique mechanisms of
action, such as targeting specific ion channels or neurotransmitters, are in
development. Furthermore, surgical interventions, including resective surgery
and laser ablation techniques, are being refined to provide better outcomes for
patients who do not respond to pharmacological treatments.
The Global Drug-Resistant Epilepsy Market is segmented
into Treatment Type, end user, regional distribution, and company.
Based on treatment type, the Global Drug-Resistant
Epilepsy Market is segmented into Neuromodulation Therapy, Antiseizure Medications,
Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment,
Specific Genetic Treatment, Immunotherapy.
Based on the Treatment Type, the antiseizure
medications segment emerged as the dominant player in the global market for
Global Drug-Resistant Epilepsy Market in 2022. This is on account of he
continuous development of new antiseizure medications and their widespread use
as the primary treatment option for individuals with drug-resistant epilepsy.
These medications play a crucial role in managing and reducing seizures,
thereby improving the quality of life for patients with this challenging
condition. Additionally, advancements in the efficacy and safety of antiseizure
medications have further solidified their position as a cornerstone of
drug-resistant epilepsy treatment, making them a key driver of the market's
growth.Based on end user, the Global Drug-Resistant Epilepsy Market is
segmented into Hospitals & Clinics, Ambulatory Care Centers, Others. Based on the
End User, the Hospital & Clincs segment emerged as the dominant player in
the global market for Global Drug-Resistant Epilepsy Market in 2022. Hospitals and clinics often have specialized
neurology departments or epilepsy centers staffed by neurologists and
epileptologists who have expertise in diagnosing and managing epilepsy,
including drug-resistant forms. These specialists can provide a higher level of
knowledge and experience in dealing with complex cases. Hospitals have
access to advanced diagnostic equipment, such as EEG (electroencephalogram)
monitoring, MRI (magnetic resonance imaging), and video monitoring, which are
crucial for accurately diagnosing drug-resistant epilepsy and determining
appropriate treatment options. In some cases, drug-resistant epilepsy may
require inpatient care, especially when intensive monitoring, medication
adjustments, or diagnostic evaluations are necessary. Hospitals can provide the
facilities and resources needed for inpatient treatment and monitoring.
North America emerged as the dominant player in the
global Drug-Resistant Epilepsy Market
in 2022, holding the largest market share. the region's advanced
healthcare infrastructure, which enables timely diagnosis and comprehensive
treatment for patients suffering from drug-resistant epilepsy. The presence of
renowned medical institutions, specialized epilepsy centers, and a robust
pharmaceutical industry contributes to North America's leading role. a surge in
research and development activities, coupled with substantial investments in
innovative treatment options, propelled North America to the forefront.
Pharmaceutical companies within the region have been at the vanguard of
developing novel drugs and therapies, aiming to address the unmet medical needs
of individuals with drug-resistant epilepsy. Furthermore, North America has
witnessed growing awareness about epilepsy, leading to early diagnosis and
intervention. Government initiatives, patient advocacy groups, and healthcare
campaigns have all played a role in raising awareness and reducing the stigma
associated with epilepsy.
Major companies operating in Global Drug-Resistant
Epilepsy Market are:
- UCB S.A.
- Jazz Pharmaceuticals
- LivaNova PLC
- NeuroPace, Inc
- Avenue Therapeutics
- Xenon Pharmaceuticals Inc.
- Marinus Pharmaceuticals
- PTC Therapeutics
- Aquestive Therapeutics
- Neuroelectrics
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Drug-Resistant Epilepsy Market is poised for significant growth in the coming
years due to several compelling factors. Firstly, the rising prevalence of
drug-resistant epilepsy itself is a driving force. Despite existing treatment
options, a substantial portion of epilepsy patients continue to experience
seizures that do not respond to conventional medications. This unmet medical
need is spurring research and development efforts to create more effective
therapies, thus expanding the market. Secondly, advancements in diagnostic
technologies, including genetic testing and imaging modalities, are enabling
more precise diagnosis and characterization of drug-resistant epilepsy. This
enhanced understanding of the condition's underlying causes is facilitating the
development of targeted treatments, driving market growth. Moreover,
pharmaceutical companies are investing heavily in the development of novel
antiepileptic drugs and therapies..” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Drug-Resistant Epilepsy Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type
(Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy
Surgery, Specific Metabolic Treatment, Specific Genetic Treatment,
Immunotherapy), By End User (Hospitals & Clinics, Ambulatory Care Centers,
Others) By Region and Competition”, has evaluated the future growth potential of Global
Drug-Resistant Epilepsy Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Drug-Resistant
Epilepsy Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com